nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—hypertension—adrenal gland cancer	0.863	1	CtDrD
Irbesartan—JUN—adrenal medulla—adrenal gland cancer	0.0186	0.387	CbGeAlD
Irbesartan—CYP1A2—urine—adrenal gland cancer	0.0026	0.0539	CbGeAlD
Irbesartan—CYP2C9—urine—adrenal gland cancer	0.00246	0.0512	CbGeAlD
Irbesartan—EDNRA—adrenal cortex—adrenal gland cancer	0.00197	0.041	CbGeAlD
Irbesartan—CYP3A4—urine—adrenal gland cancer	0.00188	0.039	CbGeAlD
Irbesartan—CYP2D6—urine—adrenal gland cancer	0.00185	0.0384	CbGeAlD
Irbesartan—JUN—adrenal cortex—adrenal gland cancer	0.0018	0.0374	CbGeAlD
Irbesartan—EDNRA—cardiac atrium—adrenal gland cancer	0.00163	0.0339	CbGeAlD
Irbesartan—EDNRA—pituitary gland—adrenal gland cancer	0.00159	0.0331	CbGeAlD
Irbesartan—JUN—gonad—adrenal gland cancer	0.00149	0.031	CbGeAlD
Irbesartan—JUN—cardiac atrium—adrenal gland cancer	0.00149	0.0309	CbGeAlD
Irbesartan—JUN—pituitary gland—adrenal gland cancer	0.00145	0.0302	CbGeAlD
Irbesartan—EDNRA—adrenal gland—adrenal gland cancer	0.00142	0.0296	CbGeAlD
Irbesartan—AGTR1—adrenal cortex—adrenal gland cancer	0.00136	0.0282	CbGeAlD
Irbesartan—JUN—adrenal gland—adrenal gland cancer	0.0013	0.027	CbGeAlD
Irbesartan—AGTR1—cardiac atrium—adrenal gland cancer	0.00112	0.0233	CbGeAlD
Irbesartan—AGTR1—pituitary gland—adrenal gland cancer	0.0011	0.0228	CbGeAlD
Irbesartan—AGTR1—adrenal gland—adrenal gland cancer	0.000979	0.0203	CbGeAlD
Irbesartan—CYP2C8—pituitary gland—adrenal gland cancer	0.000594	0.0123	CbGeAlD
Irbesartan—PTGS1—cardiac atrium—adrenal gland cancer	0.000493	0.0102	CbGeAlD
Irbesartan—PTGS1—pituitary gland—adrenal gland cancer	0.000482	0.01	CbGeAlD
Irbesartan—PTGS1—adrenal gland—adrenal gland cancer	0.00043	0.00894	CbGeAlD
Irbesartan—Candesartan—ABCB1—adrenal gland cancer	0.000407	0.608	CrCbGaD
Irbesartan—Losartan—ABCB1—adrenal gland cancer	0.000263	0.392	CrCbGaD
Irbesartan—JUN—Regulation of Telomerase—EGFR—adrenal gland cancer	0.000139	0.00158	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000139	0.00158	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GNRHR—adrenal gland cancer	0.000137	0.00155	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000136	0.00155	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—CDKN2A—adrenal gland cancer	0.000134	0.00153	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—RB1—adrenal gland cancer	0.000134	0.00153	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SDHB—adrenal gland cancer	0.00013	0.00148	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—BRAF—adrenal gland cancer	0.000128	0.00146	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000127	0.00145	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—CTNNB1—adrenal gland cancer	0.000127	0.00145	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—RB1—adrenal gland cancer	0.000126	0.00144	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—BAD—adrenal gland cancer	0.000124	0.00141	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000124	0.00141	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—TSHR—adrenal gland cancer	0.000124	0.00141	CbGpPWpGaD
Irbesartan—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.000123	0.0014	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—BRAF—adrenal gland cancer	0.000121	0.00138	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—CTNNB1—adrenal gland cancer	0.000121	0.00137	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00012	0.00136	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00012	0.00136	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—BRAF—adrenal gland cancer	0.000118	0.00134	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—BAD—adrenal gland cancer	0.000117	0.00134	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	0.000117	0.00133	CbGpPWpGaD
Irbesartan—JUN—Immune System—SH3KBP1—adrenal gland cancer	0.000115	0.00131	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TP53—adrenal gland cancer	0.000114	0.0013	CbGpPWpGaD
Irbesartan—CYP2C8—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	0.000113	0.00129	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—EGFR—adrenal gland cancer	0.000112	0.00128	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—PTGS2—adrenal gland cancer	0.000112	0.00127	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—GNAS—adrenal gland cancer	0.00011	0.00125	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000109	0.00124	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNRHR—adrenal gland cancer	0.000107	0.00122	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—BRAF—adrenal gland cancer	0.000107	0.00122	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—RB1—adrenal gland cancer	0.000107	0.00122	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000107	0.00121	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—adrenal gland cancer	0.000102	0.00117	CbGpPWpGaD
Irbesartan—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.000101	0.00115	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—adrenal gland cancer	0.000101	0.00114	CbGpPWpGaD
Irbesartan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	9.99e-05	0.00114	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SH3KBP1—adrenal gland cancer	9.97e-05	0.00113	CbGpPWpGaD
Irbesartan—CYP2C8—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	9.95e-05	0.00113	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TP53—adrenal gland cancer	9.87e-05	0.00112	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—EGFR—adrenal gland cancer	9.84e-05	0.00112	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	9.72e-05	0.00111	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TSHR—adrenal gland cancer	9.7e-05	0.0011	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—CTNNB1—adrenal gland cancer	9.64e-05	0.0011	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	9.46e-05	0.00108	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—POMC—adrenal gland cancer	9.43e-05	0.00107	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—CDKN2A—adrenal gland cancer	9.39e-05	0.00107	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ZNRF3—adrenal gland cancer	9.38e-05	0.00107	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—CTNNB1—adrenal gland cancer	9.28e-05	0.00106	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—adrenal gland cancer	9.26e-05	0.00105	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	9.22e-05	0.00105	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	9.05e-05	0.00103	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PRKACA—adrenal gland cancer	8.87e-05	0.00101	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	8.6e-05	0.000978	CbGpPWpGaD
Irbesartan—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	8.54e-05	0.000971	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—adrenal gland cancer	8.45e-05	0.000961	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—adrenal gland cancer	8.42e-05	0.000958	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SDHD—adrenal gland cancer	8.37e-05	0.000952	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—RRM1—adrenal gland cancer	8.37e-05	0.000952	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CDC42—adrenal gland cancer	8.28e-05	0.000942	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—adrenal gland cancer	8.26e-05	0.000939	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GNRH1—adrenal gland cancer	8.19e-05	0.000931	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—POMC—adrenal gland cancer	8.18e-05	0.000931	CbGpPWpGaD
Irbesartan—CYP2D6—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	8.17e-05	0.000929	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PRKACA—adrenal gland cancer	8.16e-05	0.000928	CbGpPWpGaD
Irbesartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	8.1e-05	0.000921	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—RB1—adrenal gland cancer	8.07e-05	0.000918	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—adrenal gland cancer	8.02e-05	0.000912	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—TP53—adrenal gland cancer	8.02e-05	0.000912	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNRHR—adrenal gland cancer	8.02e-05	0.000912	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—GNAS—adrenal gland cancer	7.92e-05	0.0009	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	7.89e-05	0.000898	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	7.88e-05	0.000896	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—EGFR—adrenal gland cancer	7.81e-05	0.000889	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—CTNNB1—adrenal gland cancer	7.73e-05	0.000879	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	7.69e-05	0.000875	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CDC42—adrenal gland cancer	7.52e-05	0.000856	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SPRY2—adrenal gland cancer	7.49e-05	0.000852	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—adrenal gland cancer	7.47e-05	0.00085	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SH3KBP1—adrenal gland cancer	7.45e-05	0.000847	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	7.42e-05	0.000844	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—POMC—adrenal gland cancer	7.4e-05	0.000842	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—EGFR—adrenal gland cancer	7.36e-05	0.000836	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SDHB—adrenal gland cancer	7.32e-05	0.000832	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TSHR—adrenal gland cancer	7.3e-05	0.00083	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—GNAS—adrenal gland cancer	7.19e-05	0.000817	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CDKN2A—adrenal gland cancer	7.1e-05	0.000807	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ZNRF3—adrenal gland cancer	7.01e-05	0.000797	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PRKACA—adrenal gland cancer	6.96e-05	0.000791	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—EGFR—adrenal gland cancer	6.95e-05	0.000791	CbGpPWpGaD
Irbesartan—CYP1A2—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	6.92e-05	0.000787	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CDC42—adrenal gland cancer	6.92e-05	0.000787	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—adrenal gland cancer	6.88e-05	0.000782	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MEN1—adrenal gland cancer	6.86e-05	0.000781	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—EGFR—adrenal gland cancer	6.75e-05	0.000768	CbGpPWpGaD
Irbesartan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	6.59e-05	0.000749	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—adrenal gland cancer	6.56e-05	0.000746	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CDC42—adrenal gland cancer	6.5e-05	0.000739	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—EGFR—adrenal gland cancer	6.48e-05	0.000737	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNRH1—adrenal gland cancer	6.43e-05	0.000731	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—MED12—adrenal gland cancer	6.24e-05	0.00071	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—GNAS—adrenal gland cancer	6.21e-05	0.000706	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—adrenal gland cancer	6.18e-05	0.000702	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—EGFR—adrenal gland cancer	6.12e-05	0.000696	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	6.1e-05	0.000693	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	5.97e-05	0.000679	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—adrenal gland cancer	5.97e-05	0.000679	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CDC42—adrenal gland cancer	5.9e-05	0.000671	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SPRY2—adrenal gland cancer	5.88e-05	0.000669	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	5.76e-05	0.000655	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TSHR—adrenal gland cancer	5.73e-05	0.000651	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—adrenal gland cancer	5.67e-05	0.000645	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—GNAS—adrenal gland cancer	5.64e-05	0.000641	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MEN1—adrenal gland cancer	5.39e-05	0.000613	CbGpPWpGaD
Irbesartan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	5.34e-05	0.000607	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—POMC—adrenal gland cancer	5.33e-05	0.000606	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—POMC—adrenal gland cancer	5.29e-05	0.000601	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PRKACA—adrenal gland cancer	5.24e-05	0.000596	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—adrenal gland cancer	5.23e-05	0.000594	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	5.12e-05	0.000582	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	5.1e-05	0.00058	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—adrenal gland cancer	4.91e-05	0.000559	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—POMC—adrenal gland cancer	4.84e-05	0.00055	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—BAD—adrenal gland cancer	4.83e-05	0.000549	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNRH1—adrenal gland cancer	4.8e-05	0.000546	CbGpPWpGaD
Irbesartan—JUN—Immune System—PRKACA—adrenal gland cancer	4.75e-05	0.00054	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SDHB—adrenal gland cancer	4.73e-05	0.000537	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—RRM1—adrenal gland cancer	4.71e-05	0.000536	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SDHD—adrenal gland cancer	4.71e-05	0.000536	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PRKACA—adrenal gland cancer	4.55e-05	0.000518	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDC42—adrenal gland cancer	4.44e-05	0.000505	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SPRY2—adrenal gland cancer	4.39e-05	0.000499	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	4.34e-05	0.000493	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—POMC—adrenal gland cancer	4.3e-05	0.000489	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF2—adrenal gland cancer	4.28e-05	0.000487	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TSHR—adrenal gland cancer	4.28e-05	0.000487	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GNAS—adrenal gland cancer	4.25e-05	0.000483	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—POMC—adrenal gland cancer	4.18e-05	0.000476	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	4.15e-05	0.000472	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1R—adrenal gland cancer	4.14e-05	0.000471	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PRKACA—adrenal gland cancer	4.11e-05	0.000468	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDC42—adrenal gland cancer	4.03e-05	0.000458	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MEN1—adrenal gland cancer	4.02e-05	0.000458	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—adrenal gland cancer	3.95e-05	0.000449	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SDHB—adrenal gland cancer	3.88e-05	0.000441	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SDHB—adrenal gland cancer	3.85e-05	0.000437	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—POMC—adrenal gland cancer	3.8e-05	0.000432	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	3.72e-05	0.000423	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GNAS—adrenal gland cancer	3.69e-05	0.00042	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—POMC—adrenal gland cancer	3.68e-05	0.000418	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ABCB1—adrenal gland cancer	3.62e-05	0.000412	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TERT—adrenal gland cancer	3.57e-05	0.000405	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	3.55e-05	0.000403	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MED12—adrenal gland cancer	3.52e-05	0.0004	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDC42—adrenal gland cancer	3.49e-05	0.000397	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF2—adrenal gland cancer	3.36e-05	0.000382	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNAS—adrenal gland cancer	3.33e-05	0.000379	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SDHB—adrenal gland cancer	3.29e-05	0.000374	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1R—adrenal gland cancer	3.25e-05	0.00037	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CTNNB1—adrenal gland cancer	3.18e-05	0.000361	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	3.14e-05	0.000357	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—BAD—adrenal gland cancer	3.1e-05	0.000353	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PRKACA—adrenal gland cancer	3.07e-05	0.000349	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—RRM1—adrenal gland cancer	3.05e-05	0.000346	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SDHD—adrenal gland cancer	3.05e-05	0.000346	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	3.03e-05	0.000344	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—POMC—adrenal gland cancer	2.86e-05	0.000325	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	2.84e-05	0.000323	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—BRAF—adrenal gland cancer	2.82e-05	0.000321	CbGpPWpGaD
Irbesartan—JUN—Immune System—BAD—adrenal gland cancer	2.81e-05	0.00032	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TERT—adrenal gland cancer	2.8e-05	0.000318	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—adrenal gland cancer	2.74e-05	0.000311	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDC42—adrenal gland cancer	2.61e-05	0.000296	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	2.59e-05	0.000294	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PRKACA—adrenal gland cancer	2.56e-05	0.000292	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SDHB—adrenal gland cancer	2.54e-05	0.000288	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—adrenal gland cancer	2.52e-05	0.000286	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF2—adrenal gland cancer	2.51e-05	0.000286	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	2.51e-05	0.000285	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SDHD—adrenal gland cancer	2.5e-05	0.000284	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—RRM1—adrenal gland cancer	2.5e-05	0.000284	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNAS—adrenal gland cancer	2.49e-05	0.000283	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—POMC—adrenal gland cancer	2.48e-05	0.000283	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SDHD—adrenal gland cancer	2.48e-05	0.000282	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—RRM1—adrenal gland cancer	2.48e-05	0.000282	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BAD—adrenal gland cancer	2.43e-05	0.000277	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1R—adrenal gland cancer	2.43e-05	0.000276	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MED12—adrenal gland cancer	2.27e-05	0.000258	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—POMC—adrenal gland cancer	2.24e-05	0.000255	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BRAF—adrenal gland cancer	2.22e-05	0.000252	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—adrenal gland cancer	2.15e-05	0.000244	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SDHD—adrenal gland cancer	2.12e-05	0.000241	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—RRM1—adrenal gland cancer	2.12e-05	0.000241	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TERT—adrenal gland cancer	2.09e-05	0.000238	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GNAS—adrenal gland cancer	2.08e-05	0.000236	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—adrenal gland cancer	2.04e-05	0.000232	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ABCB1—adrenal gland cancer	2.04e-05	0.000232	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	2.03e-05	0.000231	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—adrenal gland cancer	1.98e-05	0.000225	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MED12—adrenal gland cancer	1.86e-05	0.000212	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—adrenal gland cancer	1.85e-05	0.00021	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MED12—adrenal gland cancer	1.85e-05	0.00021	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BAD—adrenal gland cancer	1.82e-05	0.000207	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—POMC—adrenal gland cancer	1.68e-05	0.000191	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PRKACA—adrenal gland cancer	1.66e-05	0.000188	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—adrenal gland cancer	1.66e-05	0.000188	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	1.65e-05	0.000188	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—RRM1—adrenal gland cancer	1.63e-05	0.000186	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SDHD—adrenal gland cancer	1.63e-05	0.000186	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	1.62e-05	0.000184	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—adrenal gland cancer	1.62e-05	0.000184	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—adrenal gland cancer	1.6e-05	0.000182	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MED12—adrenal gland cancer	1.58e-05	0.00018	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—adrenal gland cancer	1.47e-05	0.000167	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	1.41e-05	0.000161	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—POMC—adrenal gland cancer	1.4e-05	0.000159	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	1.36e-05	0.000155	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—adrenal gland cancer	1.36e-05	0.000154	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PRKACA—adrenal gland cancer	1.35e-05	0.000153	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNAS—adrenal gland cancer	1.34e-05	0.000153	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	1.32e-05	0.00015	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—adrenal gland cancer	1.32e-05	0.00015	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—adrenal gland cancer	1.27e-05	0.000144	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MED12—adrenal gland cancer	1.22e-05	0.000139	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—adrenal gland cancer	1.2e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	1.15e-05	0.000131	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	1.13e-05	0.000128	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—adrenal gland cancer	1.12e-05	0.000127	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNAS—adrenal gland cancer	1.1e-05	0.000125	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNAS—adrenal gland cancer	1.09e-05	0.000124	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	1.08e-05	0.000123	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—adrenal gland cancer	1.07e-05	0.000122	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—adrenal gland cancer	1.07e-05	0.000121	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—adrenal gland cancer	9.48e-06	0.000108	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNAS—adrenal gland cancer	9.34e-06	0.000106	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	9.16e-06	0.000104	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—POMC—adrenal gland cancer	9.04e-06	0.000103	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	8.89e-06	0.000101	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—adrenal gland cancer	7.96e-06	9.05e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—POMC—adrenal gland cancer	7.42e-06	8.44e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—POMC—adrenal gland cancer	7.36e-06	8.37e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—adrenal gland cancer	7.21e-06	8.2e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNAS—adrenal gland cancer	7.21e-06	8.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	7.07e-06	8.04e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—POMC—adrenal gland cancer	6.29e-06	7.15e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	5.92e-06	6.73e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—adrenal gland cancer	5.87e-06	6.67e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	5.01e-06	5.7e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—POMC—adrenal gland cancer	4.85e-06	5.52e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	3.87e-06	4.4e-05	CbGpPWpGaD
